Optimizing the cost-effectiveness of treatment for chronic kidney disease-mineral and bone disorder

Shunsuke Goto¹, Hirotaka Komaba², Masafumi Fukagawa² and Shinichi Nishi¹

¹Division of Nephrology and Kidney Center, Kobe University Graduate School of Medicine, Kobe, Japan and ²Division of Nephrology, Endocrinology and Metabolism, Tokai University School of Medicine, Isehara, Japan

Chronic kidney disease-mineral and bone disorder (CKD-MBD) is an important risk factor in patients with CKD, and some medications for treating CKD-MBD have been recently marketed. Because assessment of health-care cost-effectiveness is growing in importance with increases in health expenditures, several cost-effectiveness analyses for new medications such as sevelamer, lanthanum carbonate, cinacalcet hydrochloride, and paricalcitol have been conducted. The results of these analyses have stimulated discussion on the efficient use of these medications and, in some cases, have affected treatment recommendation. However, most of these studies had methodological problems, one of them being that the effectiveness of medications was estimated based on changes of surrogate parameters, such as vascular calcification or serum biochemistry values. Furthermore, even if cost-effectiveness analyses were based on a given clinical trial, the results might differ from country to country. To provide greater health benefits under limited health expenditures based on the results of cost-effectiveness analyses, it is necessary to confirm the effectiveness of medications through well-designed clinical trials having mortality as the primary end point. In addition, cost-effectiveness analyses need to be performed separately for each country.

Kidney International Supplements (2013) 3, 457–461; doi:10.1038/kisup.2013.95

KEYWORDS: CKD-MBD; cost-effectiveness analysis; hyperphosphatemia; secondary hyperparathyroidism

Many patients with end-stage kidney disease have disturbances in calcium and phosphorus homeostasis. These disorders contribute to vascular calcification and bone fragility, resulting in increased risk of fracture, cardiovascular disease, and death. In 2006, a systemic disorder of mineral and bone metabolism due to chronic kidney disease (CKD) was named CKD-mineral and bone disorder (CKD-MBD).¹ Recently, several new medications for treating CKD-MBD have been marketed. In Japan, the sale of sevelamer hydrochloride began in 2003. Subsequently, the use of cinacalcet hydrochloride, lanthanum carbonate, and bixalomer began in 2008, 2009, and 2012, respectively. These medications make it easier to control CKD-MBD and thus potentially improve survival and quality of life in patients with CKD. However, a concern is that these advancements in CKD-MBD treatment may profoundly increase total CKD-related costs.

The total annual cost for treating dialysis patients in Japan is estimated to cross ¥1.3 trillion, consuming approximately 4% of the total health expenditure.² The number of dialysis patients is increasing exponentially, and it surpassed 300,000 in 2011.³ This number is expected to continue increasing for the next several years. In addition, the average age of dialysis patients is increasing, and the proportion of patients with diabetes is growing. Because aging and diabetes render patients susceptible to several other diseases, the increase in the number of patients on dialysis, average age, and the number of patients with diabetes will increase the cost for patients on dialysis.

Because health expenses are increasing, the need to control health-care costs is increasing in many countries. Therefore, the evaluation of health-care cost-effectiveness is important. Many studies from Western countries have reported the cost-effectiveness of CKD-MBD-related medications.⁴⁻²⁰ In contrast, only a few studies have investigated their cost-effectiveness in Japan.²¹,²² The results of cost-effectiveness analysis vary among races, health-care systems, and patient characteristics. Therefore, it is important to evaluate cost-effectiveness on the basis of original data obtained from each country.

Here we briefly explain the methods of assessing the cost-effectiveness of medications and then review the recent literature on cost-effectiveness analyses concerning the treatment of CKD-MBD.
APPROACH TO ASSESS COST-EFFECTIVENESS

Cost-effectiveness is assessed by comparing cost and effectiveness. If one medication is cheaper and more effective than its comparator, it is cost-effective. If one medication is both costlier and more effective, it is necessary to assess the ratio of cost to effectiveness, termed incremental cost-effectiveness ratio (ICER). If ICER is within the threshold, the medication is accepted as cost-effective. This threshold varies in different countries. Conventionally, it is $50,000–100,000 in the United States, £20,000–30,000 in the United Kingdom, and ¥5,000,000 in Japan.23

The cost and effectiveness used in most cost-effectiveness analyses are estimated from short-term clinical trials, which evaluate the effect on survival or surrogate markers. Such trials are conducted because great expense and effort are needed to conduct long-term clinical trials, which investigate lifetime cost and effectiveness. Therefore, the quality of clinical trials, whose data are used to estimate cost-effectiveness, can affect the validity of the cost-effectiveness analysis.

The effectiveness evaluated in cost-effectiveness analyses often represents life-years or life-years adjusted for quality of life. The latter is called quality-adjusted life year (QALY). The score of QALY for complete health and death is 1 and 0, respectively. For example, QALYs of hemodialysis patients, patients with cardiovascular disease, or patients with fracture were 0.52–0.72, 0.57–0.97, or 0.75–0.92, respectively, when they survived for 1 year.5,6,8,22

COST-EFFECTIVENESS ANALYSIS OF TREATMENT FOR CKD-MBD

Sevelamer

The cost-effectiveness of sevelamer has been evaluated and compared with calcium-containing phosphate binders in several studies on the basis of the results of randomized controlled trials (Table 1).4–9 Huybrechts et al. demonstrated that the use of sevelamer hydrochloride in hemodialysis patients was likely to be cost-effective in Canada7 and the United States,4 based on data of the Treat-to-Goal study.24 Taylor et al.8 showed that treatment with sevelamer conferred clinical benefits with a modest investment of additional economic resources, based on data of the Renagel in New Dialysis (RIND) study.25,26 However, the primary end points in the Treat-to-Goal and RIND studies was reduction in the progression of coronary artery calcification but not a hard outcome, such as mortality. Although the RIND study demonstrated that mortality rate of patients treated with sevelamer was lower than that of patients treated with calcium-containing binders, mortality was only a secondary end point.

The Dialysis Clinical Outcomes Revisited (DCOR) trial27 was a randomized controlled trial in which the primary end point was mortality. Although two cost-effectiveness analyses5,9 were performed on the basis of the DCOR trial, the results were contradictory. The first study demonstrated that the use of sevelamer hydrochloride as a first-line therapy was economically unattractive in hemodialysis patients.5 In contrast, the second study showed that treatment with sevelamer was more cost-effective than treatment with calcium-containing binders.9 Although the first study included dialysis costs, ICER without dialysis cost in the first analysis (CAN $77,600 per QALY gained) was much higher than ICER in the second study (£22,157 per QALY gained). The reason why the results differed is unclear. One reason may be that the difference of annual cost between calcium-containing phosphate binders and sevelamer in the first study (CANS$4125) was larger than that in the second study (£1888). Furthermore, because the DCOR trial did not show a significant effect of sevelamer on mortality (HR 0.93, 95% CI 0.79–1.10, P = 0.40), the conclusion that sevelamer is cost-effective compared with calcium-containing binders appears to be inconsistent with the DCOR results. Further clinical trials are necessary to elucidate whether sevelamer hydrochloride is cost-effective compared with calcium-containing phosphate binders.

One study was devoted to a cost-effectiveness analysis of sevelamer in pre-dialysis patients.10 In that study, the authors concluded that sevelamer as a first-line therapy was cost-effective compared with calcium carbonate. Because the study was based on the INDEPENDENT-CKD study,28 which demonstrated improved survival with sevelamer compared with calcium carbonate, this cost-effectiveness analysis seems to be valid. However, the sample size of the trial was small and the duration relatively short.

Lanthanum carbonate

Cost-effectiveness analyses of lanthanum carbonate are shown in Table 2.10–14,21 In each case, lanthanum carbonate was analyzed as additional therapy. Brennan et al.10 demonstrated that lanthanum carbonate was likely to be cost-effective in hemodialysis patients who did not achieve control of hyperphosphatemia with calcium-containing binders. However, their study did not include sevelamer hydrochloride. We conducted a clinical study investigating the effect of lanthanum carbonate on serum phosphorus levels in hemodialysis patients who did not achieve control of hyperphosphatemia with conventional medications, including sevelamer hydrochloride; subsequently, on the basis of the clinical study, we performed a cost-effectiveness analysis.21 The analysis revealed that additional administration of lanthanum carbonate would be cost-effective. Another study analyzed cost-effectiveness using the same model as Brennan et al.10 in the Canadian perspective and showed a similar result.12

Vegeter et al.11 evaluated the cost-effectiveness of lanthanum carbonate in pre-dialysis patients. In their study, the use of lanthanum carbonate reduced cost by £339 and gained 44.1 QALYs. This study also investigated the cost-effectiveness of the medication in dialysis patients. They concluded that additional therapy with lanthanum carbonate conferred good value for money, irrespective of dialysis status.

Two studies compared lanthanum carbonate with sevelamer. The study by Park et al.13 showed that lanthanum carbonate is cost-effective compared with sevelamer.
hydrochloride in end-stage renal disease patients. However, the difference in efficacy between lanthanum carbonate and sevelamer hydrochloride was only 0.025 QALYs, and the difference of serum phosphorus levels was only 0.26 mg/dl in the clinical trial that was the basis of this cost-effectiveness analysis. Because it remains unclear whether lanthanum carbonate is superior to sevelamer, it seems too early to conclude that lanthanum carbonate is cost-effective compared with sevelamer. Another study compared Canadian costs alone assuming that the efficacies were the same.12 The result was that lanthanum carbonate therapy was 23% less expensive. However, because drug prices vary by country and/or insurance system, results may differ from one country to the other.

The major limitation of these studies is that the effectiveness of lanthanum carbonate is estimated based on changes of a surrogate marker. The cost-effectiveness needs to be confirmed by an analysis based on a clinical trial with mortality as the primary outcome.

### Table 1 | Cost-effectiveness analyses of sevelamer

| Country  | Target population | Dialysis cost | Primary outcome of the clinical trial | ICER       |
|----------|-------------------|---------------|---------------------------------------|------------|
| Huybrechts4  | USA  | HD | Excluded | Vascular calcification | $2200*      |
| Manns5     | Canada | HD | Included | Mortality | CAN$157,500 |
|           |       |    | Excluded | Mortality | CAN$77,600  |
| Taylor6    | UK    | HD | Excluded | Vascular calcification | £227,120   |
| Huybrechts7 | Canada | HD | Excluded | Vascular calcification | CAN$12,384* |
| Thompson8  | UK    | HD | Excluded | Mortality | £23,878     |
| Bernard9   | UK    | Pre-dialysis | Excluded | Mortality | £22,157     |

Abbreviations: HD, hemodialysis; ICER, incremental cost-effectiveness ratio.
*Per life-year gained.
*Clinical effects in the cost-effectiveness analysis were based on mortality.

### Table 2 | Cost-effectiveness analyses of lanthanum carbonate

| Country  | Target population | Dialysis cost | Primary outcome of the clinical trial | ICER     |
|----------|-------------------|---------------|---------------------------------------|----------|
| Brennan10 | UK    | HD | Excluded | P levels | £25,033    |
| Goto11    | Japan  | HD | Excluded | P levels | $34,896     |
| Vegter11  | Canada | HD | Excluded | P levels | $6900      |
|          |       |    | Pre-dialysis | Included | Dominant |
| Vegter12  | UK    | HD | Excluded | P levels | CAN$13,200 |
| Park13    | USA   | HD | Excluded | P levels | $24,724*   |

Abbreviations: HD, hemodialysis; ICER, incremental cost-effectiveness ratio; P, phosphorus.
*vs. sevelamer hydrochloride.

### Table 3 | Cost-effectiveness analyses of cinacalcet hydrochloride

| Country  | Target population | Dialysis cost | Primary outcome of the clinical trial | ICER     | Rate of PTx (%/year) |
|----------|-------------------|---------------|---------------------------------------|----------|----------------------|
| Garside14 | UK    | HD | Excluded | PTH levels | £61,890 | 10                   |
| Ray15    | USA   | HD | Excluded | PTH levels | $17,275 | Control 4.1 |
|          |       |    |          |           |         | Cinacalcet 0.3       |
| Eandi16  | Italy  | HD | Excluded | PTH levels | £31,616 | 0.09*                |
| Komaba22 | Japan  | HD | Excluded | PTH levels | $352,631 | 100                |
|          |       |    |          |           | $21,613 | 0                   |
| Boer17   | USA   | HD | Excluded | Vascular calcification | £54,560 | 1.2                  |

Abbreviations: HD, hemodialysis; ICER, incremental cost-effectiveness ratio; PTH, parathyroid hormone; PTx, parathyroidectomy.
*Adjusted by the baseline distribution of calcium, phosphorus, and parathyroid hormone levels.
*Clinical effects in the cost-effectiveness analysis were based on calcium, phosphorus, and parathyroid hormone levels.

### Cinacalcet hydrochloride

The cost-effectiveness of cinacalcet hydrochloride is controversial (Table 3).14-17,22 A study by Garside et al.14 demonstrated that cinacalcet hydrochloride was unlikely to be considered cost-effective. In contrast, the results of three other studies led to the conclusion that the use of cinacalcet was likely to be cost-effective.15-17 One of the main explanations for this discrepancy could be a difference in the indication for parathyroidectomy in a simulation model to estimate cost and effectiveness (Table 3). We performed analyses in two types of cohorts separately: those who were eligible and those who were ineligible for parathyroidectomy.22 We found that cinacalcet was likely to be cost-effective only for those patients who were eligible for parathyroidectomy. The authors concluded that cinacalcet was not cost-effective except for those patients in whom an only brief stay on dialysis therapy was expected. Collectively, these
findings indicate that cinacalcet represents good economic value only for patients who are ineligible for parathyroidectomy, patients whose dialysis duration is expected to be short because of transplantation, and so on. In addition, because all estimates of the effectiveness of cinacalcet hydrochloride were based on changes of a surrogate marker, it is necessary to confirm the cost-effectiveness by an analysis based on the Evaluation of Cinacalcet Hydrochloride Therapy to Lower Cardiovascular Events (EVOLVE) trial\(^{10}\) that investigated the effect of cinacalcet on a composite cardiovascular end point, including mortality.

**Vitamin D receptor activators**

To the best of our knowledge, all cost-effectiveness analyses of vitamin D sterols in patients with CKD compared paricalcitol with calcitriol or alfalcacidol (Table 4).\(^{18–20}\) These studies demonstrated that the use of paricalcitol is likely to be cost-effective. However, because the effectiveness of paricalcitol in these cost-effectiveness analyses was derived from observational studies alone, it should be considered that the cost-effectiveness of paricalcitol remains unclear.

**CONCLUSION**

We reviewed cost-effectiveness analyses of therapies for CKD-MBD. Although the cost-effectiveness of some medications for CKD-MBD has been examined, it is necessary to confirm the results of these studies with future cost-effectiveness analyses based on more well-designed clinical trials. We hope that this review will stimulate a broader discussion of cost-effective therapies for CKD-MBD, with the ultimate goal to provide optimal health benefits for patients with CKD despite limited health budgets.

**ACKNOWLEDGMENTS**

This supplement was supported by a grant from the 58th Annual Meeting of the Japanese Society for Dialysis Therapy.

**DISCLOSURE**

SG has received lecture fees from Kyowa Hakko Kirin. HK has received honoraria from Kyowa Hakko Kirin and Chugai Pharmaceutical. MF has received honoraria as a speaker or an advisor/consultant to Kyowa-Hakko Kirin, Chugai, Bayer Japan Co., Ltd., and Astellas. MF has also received consulting fees from Novartis, JT, Abbvie, and a grant support from Kyowa Hakko Kirin. SN has received honoraria from Kyowa Hakko Kirin, Chugai Pharmaceutical, Bayer Yakuhin, and Novartis and has received grants/research support from Kyowa Hakko Kirin, Chugai Pharmaceutical, Bayer Yakuhin, and Novartis.

**REFERENCES**

1. Moe S, Druke T, Cunningham J et al. Definition, evaluation, and classification of renal osteodystrophy: a position statement from Kidney Disease: Improving Global Outcomes (KDOQI). Kidney Int 2006; 69: 1945–1953.
2. Fukuhara S, Yamazaki C, Hayashino Y et al. The organization and financing of end-stage renal disease treatment in Japan. Int J Health Care Finance Econ 2007; 7: 217–231.
3. Nakai S, Watanabe Y, Masakane I et al. Overview of regular dialysis treatment in Japan (as of December 31, 2011). J Jpn Soc Dial Ther 2013; 46: 1–76 (In Japanese).
4. Huybrechts KF, Caro JJ, Wilson DA et al. Health and economic consequences of sevelamer use for hyperphosphatemia in patients on hemodialysis. Value Health 2005; 8: 549–561.
5. Manns B, Klabenbach S, Lee H et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol Dial Transplant 2007; 22: 2867–2878.
6. Taylor MJ, Elgazzar HA, Chaplin S et al. An economic evaluation of sevelamer in patients new to dialysis. Curr Med Res Opin 2008; 24: 601–608.
7. Huybrechts KF, Caro JJ, O’Brien JA. Prevention and management of hyperphosphatemia with sevelamer in Canada: health and economic consequences. Value Health 2009; 12: 16–19.
8. Thompson M, Bartko-Winters S, Bernard L et al. Economic evaluation of sevelamer for the treatment of hyperphosphatemia in chronic kidney disease patients not on dialysis in the United Kingdom. J Med Econ 2013; 16: 744–755.
9. Bernard L, Mendelsohn D, Dunn E et al. A modeled economic evaluation of sevelamer for treatment of hyperphosphatemia associated with chronic kidney disease among patients on dialysis in the United Kingdom. J Med Econ 2013; 16: 1–9.
10. Brennan A, Akehurst R, Davis S et al. The cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in patients with end-stage renal disease. Value Health 2007; 10: 32–41.
11. Veger T, Tolley K, Keith MS et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney disease before and during dialysis. Value Health 2011; 14: 852–858.
12. Veger T, Tolley K, Keith MS et al. Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients: a Canadian payer perspective. Clin Ther 2012; 34: 1531–1543.
13. Park H, Rascati KL, Keith MS et al. Cost-effectiveness of lanthanum carbonate versus sevelamer hydrochloride for the treatment of hyperphosphatemia in patients with end-stage renal disease: a US payer perspective. Value Health 2011; 14: 1002–1009.
14. Garside R, Pitt M, Anderson R et al. The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol Dial Transplant 2007; 22: 1428–1436.
15. Ray JA, Borker R, Barber B et al. Cost-effectiveness of early versus late cinacalcet treatment in addition to standard care for secondary renal hyperparathyroidism in the USA. Value Health 2008; 11: 890–898.
16. Eandi M, Pradelli L, Iannazzo S et al. Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmacoeconomics 2010; 28: 1041–1054.
17. Boer R, Lalla AM, BelozeroﬀV. Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J Med Econ 2012; 15: 509–520.
18. Rosery H, Bergemann R, Marx SE et al. Health-economic comparison of paricalcitol, calcitriol and alfalcacidol for the treatment of secondary hyperparathyroidism during haemodialysis. Clin Drug Invest 2006; 26: 629–638.
19. Nuijten M, Andress DL, Marx SE et al. Chronic kidney disease Markov model comparing paricalcitol to calcitriol for secondary hyperparathyroidism: a US perspective. Curr Med Res Opin 2009; 25: 1221–1234.
20. Nuijten M, Andress DL, Marx SE et al. Cost effectiveness of paricalcitol versus a non-selective vitamin D receptor activator for secondary hyperparathyroidism in the UK: a chronic kidney disease markov model. Clin Drug Invest 2010; 30: 543–557.

| Country | Target population | Dialysis cost | Primary outcome of the clinical trial | ICER |
|---------|------------------|---------------|--------------------------------------|------|
| Rosery\(^{18}\) | Germany | HD | Excluded\(^{a}\) | Dominant |
| Nuijten\(^{19}\) | Germany | Pre-dialysis | Included | Mortality\(^{b}\), hospitalization\(^{b}\) |
| Nuijten\(^{20}\) | USA | Pre-dialysis | Included | Mortality\(^{b}\), hospitalization\(^{b}\), proteinuria |
| Nuijten\(^{20}\) | USA | Pre-dialysis | Included | Mortality\(^{b}\), hospitalization\(^{b}\) |
| Kirin, Chugai Pharmaceutical, Bayer Yakuhin, and Novartis. | | | | £6933 |

Abbreviations: HD, hemodialysis; ICER, incremental cost-effectiveness ratio.

\(^{a}\)May include dialysis cost in hospital stay.

\(^{b}\)Data were derived from observational studies.
21. Goto S, Komaba H, Moriwaki K et al. Clinical efficacy and cost-effectiveness of lanthanum carbonate as second-line therapy in hemodialysis patients in Japan. *Clin J Am Soc Nephrol* 2011; 6: 1375–1384.

22. Komaba H, Moriwaki K, Goto S et al. Cost-effectiveness of cinacalcet hydrochloride for hemodialysis patients with severe secondary hyperparathyroidism in Japan. *Am J Kidney Dis* 2012; 60: 262–271.

23. Shiroiwa T, Sung YK, Fukuda T et al. International survey on willingness-to-pay (WTP) for one additional QALY gained: what is the threshold of cost effectiveness? *Health Econ* 2010; 19: 422–437.

24. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. *Kidney Int* 2002; 62: 245–252.

25. Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. *Kidney Int* 2005; 68: 1815–1824.

26. Block GA, Raggi P, Bellasi A et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. *Kidney Int* 2007; 71: 438–441.

27. Suzuki WN, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. *Kidney Int* 2007; 72: 1130–1137.

28. Di Iorio B, Bellasi A, Russo D, INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. *Clin J Am Soc Nephrol* 2012; 7: 487–493.

29. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. *Am J Kidney Dis* 2007; 49: 801–813.

30. Chertow GM, Block GA, Correa-Rotter R, et al. EVOLVE Trial Investigators Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. *N Engl J Med* 2012; 367: 2482–2494.